Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · Real-Time Price · USD
4.720
+0.260 (5.83%)
At close: Jul 6, 2026, 4:00 PM EDT
4.800
+0.080 (1.69%)
After-hours: Jul 6, 2026, 7:58 PM EDT
Zentalis Pharmaceuticals Employees
Zentalis Pharmaceuticals had 106 employees as of December 31, 2025. The number of employees decreased by 60 or -36.14% compared to the previous year.
Employees
106
Change (1Y)
-60
Growth (1Y)
-36.14%
Revenue / Employee
n/a
Profits / Employee
-$1,171,066
Market Cap
336.00M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 106 | -60 | -36.14% |
| Dec 31, 2024 | 166 | -2 | -1.19% |
| Dec 31, 2023 | 168 | 12 | 7.69% |
| Dec 31, 2022 | 156 | -21 | -11.86% |
| Dec 31, 2021 | 177 | 53 | 42.74% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bicycle Therapeutics | 288 |
| Lyell Immunopharma | 161 |
| Foghorn Therapeutics | 106 |
| Neumora Therapeutics | 92 |
| SAB Biotherapeutics | 86 |
| Lineage Cell Therapeutics | 77 |
| Cartesian Therapeutics | 75 |
| InflaRx | 65 |
ZNTL News
- 21 days ago - Zentalis assumed with an Outperform at Oppenheimer - TheFly
- 4 weeks ago - Zentalis Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 5 weeks ago - Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy - GlobeNewsWire
- 5 weeks ago - Zentalis Pharmaceuticals Proxy statement: Proxy filing - Filings
- 5 weeks ago - Zentalis Pharmaceuticals Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Transcripts
- 6 weeks ago - Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 - GlobeNewsWire
- 6 weeks ago - Zentalis Pharmaceuticals Transcript: Stifel 2026 Targeted Oncology Virtual Forum - Transcripts